Citi raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $71 from $69 and keeps a Buy rating on the shares. The firm updated the company’s model to reflect its better than expected Q4 revenue figures.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- Rigel: Strengthening Commercial Trajectory, Clear Path to 2026 Profitability, and Advancing Pipeline Support Buy Rating
- Rigel Announces Strong Preliminary 2025 Results and Outlook
- Rigel Pharmaceuticals sees Q4 revenue $69.8M, consensus $66.44M
- Rigel Pharmaceuticals sees FY26 revenue $275M-$290M, consensus $291.58M
- Rigel Pharmaceuticals Reports Promising Phase 1b Study Results